- Home
- CRNX vs HLN Comparison
CRNX vs HLN Comparison
Compare CRNX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | HLN |
|---|---|---|
| Founded | 2008 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 41.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNX | HLN |
|---|---|---|
| Price | $48.27 | $10.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | ★ $71.00 | N/A |
| AVG Volume (30 Days) | 992.2K | ★ 10.1M |
| Earning Date | 11-06-2025 | 07-31-2025 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | N/A | ★ 41.64 |
| EPS | N/A | ★ 0.23 |
| Revenue | $1,535,000.00 | ★ $15,096,588,575.00 |
| Revenue This Year | $425.41 | $1.51 |
| Revenue Next Year | $943.30 | $4.67 |
| P/E Ratio | ★ N/A | $21.47 |
| Revenue Growth | ★ 47.74 | N/A |
| 52 Week Low | $24.10 | $8.71 |
| 52 Week High | $54.18 | $11.42 |
Technical Indicators
Market Signals| Indicator | CRNX | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 66.93 |
| Support Level | $43.04 | $9.82 |
| Resistance Level | $49.61 | $9.65 |
| Average True Range (ATR) | 2.04 | 0.13 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 62.22 | 97.09 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.